A randomized, double-blind, placebo-controlled study of botulinum toxin type A for the treatment of glabellar lines: determination of optimal dose.

@article{Monheit2007ARD,
  title={A randomized, double-blind, placebo-controlled study of botulinum toxin type A for the treatment of glabellar lines: determination of optimal dose.},
  author={Gary Monheit and Alastair Carruthers and Fredric Brandt and R Peter Rand},
  journal={Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.]},
  year={2007},
  volume={33 1 Spec No.},
  pages={S51-9}
}
BACKGROUND Botulinum toxin is used to treat glabellar lines, but the optimal dose of Reloxin (Dysport, Ipsen Biopharm Ltd.) for this indication remains to be established. OBJECTIVE The objective was to evaluate three doses of Reloxin to determine its efficacy and safety in treating glabellar lines. METHODS AND MATERIALS Participants were given 20, 50, or 75 U of Reloxin, or placebo, injected across the glabella. Follow-up was on Days 7, 30, 60, 90, and 120. Adverse events were also elicited… CONTINUE READING

From This Paper

Topics from this paper.

Citations

Publications citing this paper.
Showing 1-10 of 44 extracted citations

Similar Papers

Loading similar papers…